Poland has rapidly grown into a high-potential destination for clinical trials in Central and Eastern Europe, driven by ongoing healthcare modernization, expanding research infrastructure, and a strong medical talent base. With a population of around 37 million, Poland offers access to large and diverse patient groups - an important advantage for patient recruitment and study feasibility. As an EU Member State, Poland operates within a regulatory framework aligned with European requirements and ICH-GCP standards, supporting globally acceptable trial conduct and documentation. Today, sponsors and CROs increasingly choose clinical trials in Poland for a balance of quality, scale, and cost efficiency.
Poland stands out as a competitive location for clinical research thanks to its extensive network of academic hospitals, specialized outpatient clinics, and experienced investigators with strong track records in multinational studies. Regulatory and ethics review processes follow EU-aligned rules, with standardized submissions and clear requirements that help sponsors plan timelines and resources more predictably.
From a budget perspective, Poland is often more cost-effective than Western Europe while still delivering EU-level compliance, robust oversight, and dependable data quality - making it a strong option for Phase II–IV trials, post-authorization studies, and large multicenter programs. Poland is particularly active in therapeutic areas such as oncology, cardiology, neurology, endocrinology/diabetes, immunology, and rare diseases, supported by modern diagnostics, imaging, and laboratory capabilities.
Operationally, sponsors benefit from GCP-trained site staff and a strong culture of protocol adherence - factors that can improve enrollment stability, retention, and overall study performance. The result is a setting where high-quality clinical data can be generated to support both European submissions and broader global development strategies.
Poland’s clinical research landscape continues to expand, with growing site networks, increasing investigator specialization, and rising adoption of hybrid and decentralized trial elements. Combined with a large patient pool and EU-aligned standards, Poland is well-positioned for sponsors seeking reliable enrollment, strong data integrity, and cost-efficient clinical trials - all in one of Europe’s most dynamic research markets.
